OTCM
ADXS
Market cap25mUSD
Feb 03, Last price
0.60USD
Name
Ayala Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
1,977.51
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.87%
Rev. gr., 5y
-70.74%
Revenues
13k
-94.80%
Net income
-48m
L+234.79%
CFO
-29m
L+92.91%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ayala Pharmaceuticals, Inc., a clinical-stage oncology firm, focuses on developing and commercializing small molecule therapies for individuals battling rare tumors and aggressive cancers. Its primary drug candidates currently in development include AL102, an oral gamma secretase inhibitor for desmoid tumors, and aspacytarabine (BST-236), an innovative, proprietary anti-metabolite designed for first-line treatment in acute myeloid leukemia patients who are considered unfit. The company is headquartered in Wilmington, Delaware.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2022‑10 | 2022‑01 | 2021‑10 | 2021‑01 | 2020‑10 | 2020‑01 | 2019‑10 | 2019‑01 | 2018‑10 | 2018‑01 | 2017‑10 | 2017‑01 | 2016‑10 | |
| Income | |||||||||||||||
Revenues | |||||||||||||||
Cost of revenue | |||||||||||||||
Unusual Expense (Income) | |||||||||||||||
NOPBT | |||||||||||||||
NOPBT Margin | |||||||||||||||
Operating Taxes | |||||||||||||||
Tax Rate | |||||||||||||||
NOPAT | |||||||||||||||
Net income | |||||||||||||||
Dividends | |||||||||||||||
Dividend yield | |||||||||||||||
Proceeds from repurchase of equity | |||||||||||||||
BB yield | |||||||||||||||
| Debt | |||||||||||||||
Debt current | |||||||||||||||
Long-term debt | |||||||||||||||
Deferred revenue | |||||||||||||||
Other long-term liabilities | |||||||||||||||
Net debt | |||||||||||||||
| Cash flow | |||||||||||||||
Cash from operating activities | |||||||||||||||
CAPEX | |||||||||||||||
Cash from investing activities | |||||||||||||||
Cash from financing activities | |||||||||||||||
FCF | |||||||||||||||
| Balance | |||||||||||||||
Cash | |||||||||||||||
Long term investments | |||||||||||||||
Excess cash | |||||||||||||||
Stockholders' equity | |||||||||||||||
Invested Capital | |||||||||||||||
ROIC | |||||||||||||||
ROCE | |||||||||||||||
| EV | |||||||||||||||
Common stock shares outstanding | |||||||||||||||
Price | |||||||||||||||
Market cap | |||||||||||||||
EV | |||||||||||||||
EBITDA | |||||||||||||||
EV/EBITDA | |||||||||||||||
Interest | |||||||||||||||
Interest/NOPBT | |||||||||||||||